NYSEAMERICAN:PFNX - Pfenex Stock Price, Forecast & News

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

Pfenex Inc (NYSEAMERICAN:PFNX) posted its earnings results on Thursday, November, 7th. The biotechnology company reported $0.09 earnings per share for the quarter, meeting analysts' consensus estimates of $0.09. The biotechnology company earned $15.25 million during the quarter, compared to analysts' expectations of $14.80 million. View Pfenex's Earnings History.

Pfenex is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Pfenex.

4 equities research analysts have issued 1 year price targets for Pfenex's stock. Their forecasts range from $17.00 to $20.00. On average, they expect Pfenex's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 74.2% from the stock's current price. View Analyst Price Targets for Pfenex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

News coverage about PFNX stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfenex earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Pfenex.

Pfenex saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 890,400 shares, an increase of 68.3% from the September 15th total of 529,100 shares. Based on an average daily trading volume, of 320,500 shares, the short-interest ratio is currently 2.8 days. Currently, 2.8% of the company's stock are short sold. View Pfenex's Current Options Chain.

Some companies that are related to Pfenex include Concordia International (CXR), Polynovo (PNV), Kodiak Sciences (KOD), Immutep (IMM), Mesoblast (MSB), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Oxford BioMedica (OXB), Starpharma (SPL), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Biotest (BIO), Bellus Health (BLU), Neptune Wellness Solutions (NEPT) and ProMetic Life Sciences (PLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Ocular Therapeutix (OCUL), Fate Therapeutics (FATE), Opko Health (OPK), Relypsa (RLYP), Spectrum Pharmaceuticals (SPPI), TherapeuticsMD (TXMD), Verastem (VSTM), Alder Biopharmaceuticals (ALDR), Coherus Biosciences (CHRS) and Dicerna Pharmaceuticals (DRNA).

Pfenex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.74%), Millennium Management LLC (0.82%), Squarepoint Ops LLC (0.55%), Russell Investments Group Ltd. (0.48%), Commonwealth Equity Services LLC (0.25%) and Point72 Asset Management L.P. (0.24%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

PFNX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Man Group plc, Zurcher Kantonalbank Zurich Cantonalbank, Commonwealth Equity Services LLC and Barclays PLC. View Insider Buying and Selling for Pfenex.

PFNX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Point72 Asset Management L.P., State Street Corp, Delta Investment Management LLC, Metropolitan Life Insurance Co NY, California Public Employees Retirement System and California State Teachers Retirement System. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PFNX stock can currently be purchased for approximately $10.62.

Pfenex has a market capitalization of $336.40 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

The official website for Pfenex is http://www.pfenex.com/.

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.